Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840809 | 0.84 | LMNA (0.60) | OPRM1LMNAMEN1POLBKMT2A | |
| SCHEMBL7769506 | 0.81 | MEN1 (0.43) | LMNAMAPTMEN1POLBKMT2A | |
| SCHEMBL6841091 | 0.80 | HSD11B1 (0.42) | LMNAKDM2BMAPTMEN1POLB | |
| Chlorobenzene SCHEMBL28751594 | 0.79 | OPRM1 (0.46) | OPRM1OPRL1HRH3KDM2BMEN1 | |
| Hydrochloric Acid SCHEMBL8875080 | 0.71 | OPRM1 (0.53) | OPRM1OPRL1HRH3LMNAKDM2B | |
| SCHEMBL2460473 | 0.71 | OPRM1 (0.53) | OPRM1OPRL1LMNAKDM2BTP53 | |
| SCHEMBL2460474 | 0.71 | OPRM1 (0.53) | OPRM1OPRL1LMNAKDM2BTP53 | |
| SCHEMBL17590663 | 0.71 | ALDH1A1 (0.40) | MEN1KMT2A | |
| SCHEMBL13636510 | 0.71 | HRH3 (0.66) | HRH3LMNAMAPTMEN1POLB | |
| Hydrochloric Acid SCHEMBL5063044 | 0.70 | HRH3 (0.68) | HRH3LMNAMAPTMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1635998-A | Tricyclic analgesics | WARNER LAMBERT CO (US) | 2005-07-06 | — | — | CN | disclosed |
| US-20040266802-A1 | Tricyclic analgesics | CALVET ALAIN (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1235808-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000075116-A2 | TRICYCLIC ANALGESICS | WARNER-LAMBERT COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266802-A1 | Tricyclic analgesics | OPRM1, OPRL1, OPRD1 | OPRM1 1/4885OPRL1 2/4885HRH3 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.